Neurosterix Advances NTX-253 For Schizophrenia Phase 1 Study
23 Apr 2026 //
GLOBENEWSWIRE
Neurosterix Launches Phase 1 Study of NTX-253 in Schizophrenia
07 Jan 2026 //
GLOBENEWSWIRE
Addex Reports 2024 Financial Results and Corporate Update
25 Apr 2025 //
GLOBENEWSWIRE

Market Place
Sourcing Support